

Appendix 4E

Preliminary Final Report

1. Company details

Name of entity

Pro Medicus Limited

ABN or equivalent
company reference

25 006 194 752

Financial year ended
(‘current period’)

30 June 2014

Financial year ended
(‘previous period’)

30 June 2013

2. Results for announcement to the market

ASX Listing Rules Ref		2014 A\$'000	2013 A\$'000	% change
2.1	Revenue from continuing operations	14,447	11,374	27.1%
2.2	Underlying profit (net profit after tax minus one off contributions)	1,580	(646)	344.6%
	Significant one off items (Sale of Amira/Impairment/Currency gains/(losses))	(70)	5,777	(101.2)%
	Profit/(Loss) from ordinary activities after tax attributable to members	1,509	5,131	(70.6%)
2.3	Net Profit/(Loss) for the period attributable to members	1,509		
	% change up/(down) of Net Profit/(Loss) for the period attributable to members from the previous corresponding period.	Down 70.6%		

2.4	Dividends (distributions)	Amount per security	Fully Franked amount per security
	Franked dividend amount per security		
	Final Dividend	1.0 cents	1.0 cents
	Interim dividend	1.0 cents	1.0 cents
2.5	Record date for Final dividends	12 September 2014	
	Payment date for Final dividends	3 October 2014	

<p>2.6</p>	<p>Australia The Group employs 26 people in Australia who undertake research and development of Pro Medicus products (RIS) as well as sales and service/support functions.</p> <p>The Group's Australian revenue was 12.2% above last year' as a result of new sales of both the Visage PACS and Visage RIS products with many sales being for the combined product offering. A growing percentage of these sales being based on the company's transaction revenue model.</p> <p>Promedicus.net, the company's e-health offering, continued to hold its strong market position despite increasing competition.</p> <p>North America The Group employs 11 people in North America to fulfil the sales marketing and professional services roles. Revenue from North America increased by 85.1% compared to the previous year. This was largely attributable to new sales and an increase in transaction based revenue from sales of Visage technology as more contracts came on stream.</p> <p>Europe The Group employs 32 employees in its Berlin office who undertake research and development of Visage Imaging products worldwide as well as sales, marketing and service/support functions for the group's European operations. Revenue from our European operations was in line with the previous year increasing by 0.14%</p> <p>Financials Reported profit after tax for the period was \$1.51m a decrease of \$3.62m (70.6%) from the previous year. Full year revenue of the Group from continuing operations, increased from \$11.37m to \$14.45m, an increase of 27.1%. The result from the underlying operations for the year was a profit of \$1.58m compared to an underlying loss of \$0.65m from the previous year. The underlying profit is made up of reported profit after-tax of \$1.51m and adding back the after-tax net currency loss of \$0.07m. Last year's underlying loss was made up of reported profit after-tax of \$5.13m, less the after-tax profit of \$8.61m from the sale of the Amira business and after-tax net currency gain of \$0.39m, and adding back the after-tax impairment expense of \$3.22m. The key driver of the underlying profit increase was the significant improvement in the performance of the North American operations supplemented by the increase in Australian sales.</p> <p>Shareholder Returns The directors are confident that the holdings of reserve cash is sufficient to underpin the development and expansion needs of the company as the business looks to increase its penetration of existing markets.</p>
<p>3.</p>	<p>Statement of Comprehensive Income Please refer to the Statement of Comprehensive Income in the attached Financial Statements.</p>
<p>4.</p>	<p>Statement of Financial Position Please refer to the Statement of Financial Position in the attached Financial Statements.</p>
<p>5.</p>	<p>Statement of cash flows Please refer to the Statement of cash flows in the attached Financial Statements.</p>

6.	<p>Details of Dividends</p> <table data-bbox="1181 212 1452 280"> <thead> <tr> <th></th> <th style="text-align: right;">2014 \$'000</th> <th style="text-align: right;">2013 \$'000</th> </tr> </thead> <tbody> <tr> <td>Final Dividend</td> <td></td> <td></td> </tr> <tr> <td>A Final Dividend of 1.0 cents (2013: 1.0 cents) per share fully franked will be paid on 3 October 2014.</td> <td style="text-align: right;">1,002</td> <td style="text-align: right;">1,002</td> </tr> <tr> <td>Current Year Interim</td> <td></td> <td></td> </tr> <tr> <td>An interim dividend of 1.0 cents (2013: 1.0 cents) per share fully franked was paid on 21 March 2014.</td> <td style="text-align: right;">1,002</td> <td style="text-align: right;">1,002</td> </tr> <tr> <td colspan="3">No foreign sourced dividend or distribution is included in either the interim or final dividends.</td> </tr> </tbody> </table>		2014 \$'000	2013 \$'000	Final Dividend			A Final Dividend of 1.0 cents (2013: 1.0 cents) per share fully franked will be paid on 3 October 2014.	1,002	1,002	Current Year Interim			An interim dividend of 1.0 cents (2013: 1.0 cents) per share fully franked was paid on 21 March 2014.	1,002	1,002	No foreign sourced dividend or distribution is included in either the interim or final dividends.		
	2014 \$'000	2013 \$'000																	
Final Dividend																			
A Final Dividend of 1.0 cents (2013: 1.0 cents) per share fully franked will be paid on 3 October 2014.	1,002	1,002																	
Current Year Interim																			
An interim dividend of 1.0 cents (2013: 1.0 cents) per share fully franked was paid on 21 March 2014.	1,002	1,002																	
No foreign sourced dividend or distribution is included in either the interim or final dividends.																			
7.	<p>Dividend or Distribution reinvestment plans</p> <p>There are no dividend or distribution reinvestment plans in operation.</p>																		
8.	<p>Statement of Retained Earnings</p> <p>Please refer to Statement of Changes in Equity in the attached Financial Statements.</p>																		
9.	<table data-bbox="383 929 1452 1019"> <thead> <tr> <th></th> <th style="text-align: right;">2014</th> <th style="text-align: right;">2013</th> </tr> </thead> <tbody> <tr> <td>Net Tangible Assets per security</td> <td></td> <td></td> </tr> <tr> <td>Net Tangible Assets per security</td> <td style="text-align: right;">\$0.13</td> <td style="text-align: right;">\$0.15</td> </tr> </tbody> </table>		2014	2013	Net Tangible Assets per security			Net Tangible Assets per security	\$0.13	\$0.15									
	2014	2013																	
Net Tangible Assets per security																			
Net Tangible Assets per security	\$0.13	\$0.15																	
10.	<p>Details of entities over which control has been gained or lost during the period</p> <p>There are no entities over which control has been gained or lost during the period</p>																		
11.	<p>Associates and joint venture entities</p> <p>There are no associates or joint venture entities</p>																		
12.	<p>Other significant information needed by an investor to make an informed assessment of the entity's financial performance and financial position.</p> <p>Please refer to section 2.6</p>																		
13.	<p>Foreign Entity accounting standards</p> <p>Australian Accounting Standards & International Financial Reporting Standards</p>																		

14.	<p>Commentary on results for the period. The earnings per security and the nature of any dilution aspects. Please refer to Note 9 of the attached Financial Statements.</p> <p>Returns to shareholders including distributions and buy backs. Please refer to Note 10 of the attached Financial Statements.</p> <p>Significant features of operating performance. Please refer to section 2.6.</p> <p>The results of segments that are significant to an understanding of the business. Please refer to Note 5 of the attached Financial Statements.</p> <p>Discussion of trends in performance. Please refer to section 2.6.</p>
15.	<p>Audit Statement</p> <p>This report is based on accounts to which one of the following applies. (Tick one)</p> <p><input checked="" type="checkbox"/> The *accounts have been audited. <input type="checkbox"/> The *accounts have been subject to review.</p> <p><input type="checkbox"/> The *accounts are in the process of being audited. <input type="checkbox"/> The *accounts have <i>not</i> yet been audited or reviewed.</p>

Sign here:

Date: 22 August 2014



Print name: Sam Hupert
Chief Executive Officer